Core Insights - Biomerica, Inc. reported a 5% year-over-year increase in total revenue for the second quarter of fiscal 2025, achieving sustained revenue growth, improved gross margins, and significant cost savings [1][4]. Financial Performance - For the fiscal second quarter of 2025, Biomerica reported net sales of $1.64 million, up from $1.57 million in the same quarter of the previous year, indicating a 5% growth driven by demand from both new and existing customers [5]. - Gross margins improved from 21% in Q2 FY2024 to 27% in Q2 FY2025, attributed to a favorable sales mix and reduced direct labor costs [7]. - Operating expenses decreased by 26% year-over-year to $1.43 million, down from $1.93 million, due to efficiencies from workforce reductions and streamlined operations [7]. - The operating loss decreased by 39% to $990,000 from $1.6 million, while the net loss reduced by 37% to $950,000 from $1.5 million, reflecting strategic cost savings and operational enhancements [8]. Product Development and Market Opportunities - The company launched the inFoods IBS test, allowing patients to order the test directly online, which identifies trigger foods causing IBS symptoms [2]. - Biomerica secured three key patents for inFoods technology, addressing multi-billion-dollar market opportunities in GERD ($4.0 billion+), Crohn's Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) [2]. - The company is expanding distribution partnerships in the U.S. and internationally to broaden the availability of inFoods IBS [3]. Strategic Focus - The CEO emphasized the company's commitment to achieving cash flow break-even and pursuing near-term opportunities to enhance financial performance [10].

Financial Performance - For the three months ended November 30, 2024, consolidated net sales were approximately $1,636,000, representing an increase from $1,567,000 for the same period in 2023[49]. - For the three months ended November 30, 2024, total revenue was approximately $1,636,000, a 4.4% increase compared to $1,567,000 for the same period in 2023[76]. - Clinical lab product sales for the six months ended November 30, 2024, were approximately $2,057,000, down 9.9% from $2,283,000 in 2023[76]. - Over-the-counter product sales increased by 34.5% to $596,000 for the three months ended November 30, 2024, compared to $443,000 in 2023[76]. Cash and Assets - As of November 30, 2024, the company reported an accumulated deficit of approximately $50.5 million and cash and cash equivalents of approximately $2,372,000[34]. - Total gross inventory as of November 30, 2024, was approximately $2,258,000, with net inventory of $1,789,000 after accounting for reserves[60]. - The Company had approximately $85,000 in advances from domestic customers as of November 30, 2024, representing prepayments for future shipments[75]. Share Issuance and Proceeds - The company sold 1,515,348 shares of common stock during the six months ended November 30, 2024, resulting in net proceeds of approximately $567,000 from the May 2024 ATM offering[41]. - The Company sold 1,515,348 shares of common stock during the six months ended November 30, 2024, generating gross proceeds of approximately $603,000[92]. - The company filed a new "shelf" registration statement on Form S-3 with the SEC on September 28, 2023, allowing the issuance of up to $20,000,000 in common shares[39]. Expenses and Cost Management - Research and development expenses for the three months ended November 30, 2024, were approximately $257,000, a decrease of 37.6% from $412,000 in 2023[79]. - Share-based compensation expenses for the six months ended November 30, 2024, were approximately $232,000, down 20.5% from $292,000 in 2023[71]. - The company executed a workforce reduction of nearly 15% in July 2024 as part of its cost-cutting measures[45]. Lease Obligations - The Company has a total operating lease cost of $93,000 for the three months ended November 30, 2024, compared to $91,000 for the same period in 2023, reflecting a 2.2% increase[98]. - For the six months ended November 30, 2024, the total lease cost is $185,000, slightly up from $183,000 in 2023, indicating a 1.1% increase[98]. - The Company’s cash paid for operating lease liabilities for the six months ended November 30, 2024, was $182,000, compared to $177,000 in 2023, representing a 2.8% increase[99]. - The weighted-average remaining lease term is 1.07 years as of November 30, 2024, down from 2.77 years in 2023[99]. - The total minimum future lease payments amount to $661,000, with $371,000 due in 2025[99]. - The Company has a weighted-average discount rate of 6.50% for its lease liabilities, unchanged from the previous year[99]. Legal Proceedings - There are no material legal proceedings pending as of November 30, 2024, indicating a stable legal environment for the Company[101]. - The Company is involved in legal proceedings that could potentially affect future operating results, but management believes these will not have a material adverse effect on its financial position[100]. Customer Concentration - The company had four key customers in the Middle East, Asia, and Europe that accounted for 58% of net consolidated sales for the three months ended November 30, 2024[50].

Core Insights - Biomerica has received three patent notices of allowance in Europe for its inFoods® Technology, targeting significant markets for GERD, Crohn's Disease, and Ulcerative Colitis, which are valued at over $4 billion, $2.5 billion, and $1.9 billion respectively [1][4][5] Market Potential - The GERD treatment market in Europe exceeds $4 billion annually, with a prevalence of symptoms affecting 8.8% to 25.9% of Europeans weekly [3] - The market for Crohn's Disease treatments in Europe is estimated at $2.5 billion annually, indicating a need for innovative treatment approaches [4] - The European market for Ulcerative Colitis is projected to grow from $1.5 billion in 2023 to over $1.9 billion by 2028 [4] Company Developments - The recent patent allowances mark a significant milestone for Biomerica in enhancing patient care through personalized medical solutions [5] - Biomerica's inFoods® Technology is a diagnostic-guided platform that identifies specific foods triggering symptoms in patients, allowing for personalized dietary plans [6][7] - The company is currently marketing inFoods® for IBS, which is already protected by 15 patents globally, and aims to expand its offerings to include treatments for GERD, Crohn's Disease, and Ulcerative Colitis [5][8] Product Benefits - inFoods® offers a non-drug, dietary-based solution for GERD, presenting a safer alternative to proton pump inhibitors, which are linked to serious health risks [7] - For Crohn's Disease and Ulcerative Colitis, inFoods® supports tailored dietary interventions that may reduce symptom severity and healthcare costs [7]

Core Insights - Biomerica, Inc. has enhanced its inFoods® IBS platform, allowing US consumers to order the inFoods® IBS test online and collect samples at home with physician oversight [1][2][6] - The inFoods® IBS test offers a personalized, non-invasive solution for managing Irritable Bowel Syndrome (IBS) symptoms by identifying specific food triggers [2][3] - A recent clinical study showed that the inFoods® IBS test significantly improved key IBS symptoms, such as Abdominal Pain Intensity (API) and bloating, without the side effects associated with traditional drug therapies [4][8] Company Overview - Biomerica, Inc. is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products for medical conditions, particularly gastrointestinal and inflammatory diseases [7] - The company aims to enhance health and well-being while reducing healthcare costs through its innovative products [7] Industry Context - IBS affects approximately 1 in 20 Americans, leading to an estimated $10 billion in annual direct medical costs, highlighting the economic burden of the condition [5] - The complexity of IBS often leaves patients struggling to find effective treatments, creating a significant market opportunity for personalized solutions like the inFoods® IBS test [5][6]

Core Insights - Biomerica reported a 6% increase in total revenue for the first quarter of fiscal 2025, reaching $1.8 million compared to $1.7 million in the same period last year, driven by higher demand and new contracts [3][7] - The company has implemented cost-saving measures expected to reduce annual expenses by 16% to 23%, translating to savings of $1.0 million to $1.4 million [4] - Biomerica's at-home PSA screening test has received approval from the Saudi Food and Drug Authority, enhancing accessibility for early prostate cancer detection [2] Financial Performance - Revenue for the first quarter of fiscal 2025 was $1.8 million, up from $1.7 million in the prior year [3][7] - Gross margin decreased to 16% from 24% year-over-year, impacted by one-time reduction-in-force costs [4][7] - Operating expenses rose slightly to $1.7 million from $1.6 million, primarily due to severance costs and new sales force expenses [5][7] - Operating loss increased to $1.4 million from $1.2 million, while net loss rose to $1.3 million from $1.1 million, largely due to RIF-related expenses [6][7] Product Developments - The inFoods® IBS pilot program with a group of 1,100 physicians has been completed, with potential for a systemwide launch based on positive results [2] - Biomerica is exploring distribution partnerships for inFoods® IBS to expand its market reach [2] - The company is in discussions with major clinical laboratories for its hp+detect™ product, which offers cost-effective and superior detection of Helicobacter pylori [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbols Name of each exchange on which registered Common Stock, par value $0.08 BMRA Nasdaq Capital Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37 ...

- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) is pleased to announce that the Saudi Food and Drug Authority (SFDA) has approved the Company's Fortel® Prostate (PSA) Screening Test to be sold and used in the country. This at-home test is designed to empower men with the ability to detect early w ...

Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger Growth Significant Cost Savings Plan Implemented After Year End – Expected to Deliver Expense Reductions of $1.0 to $1.4 Million in the Coming Year inFoods® IBS Pilot with Large 1,100 Physician Group Progressing Ahead of Schedule IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2024. The Company ac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbols Name of each exchange on which registered Common Stock, par value $0.08 BMRA Nasdaq Capital Market FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Transition Period From ______ To ______ Commission File Number: 001 ...

Impact of IBS and Economic Burden Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica prima ...